280 related articles for article (PubMed ID: 23561304)
1. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany.
Iyer S; Taylor-Stokes G; Roughley A
Lung Cancer; 2013 Aug; 81(2):288-93. PubMed ID: 23561304
[TBL] [Abstract][Full Text] [Related]
2. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study.
Iyer S; Roughley A; Rider A; Taylor-Stokes G
Support Care Cancer; 2014 Jan; 22(1):181-7. PubMed ID: 24026981
[TBL] [Abstract][Full Text] [Related]
3. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Belani CP; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Fossella F;
Lung Cancer; 2006 Aug; 53(2):231-9. PubMed ID: 16787687
[TBL] [Abstract][Full Text] [Related]
4. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data.
Larsson M; Ljung L; Johansson BB
Eur J Cancer Care (Engl); 2012 Sep; 21(5):642-9. PubMed ID: 22519874
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting.
Chouaid C; Agulnik J; Goker E; Herder GJ; Lester JF; Vansteenkiste J; Finnern HW; Lungershausen J; Eriksson J; Kim K; Mitchell PL
J Thorac Oncol; 2013 Aug; 8(8):997-1003. PubMed ID: 23787802
[TBL] [Abstract][Full Text] [Related]
7. Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index.
Magasi S; Mallick R; Kaiser K; Patel JD; Lad T; Johnson ML; Kaplan EH; Cella D
Clin Lung Cancer; 2013 May; 14(3):245-53. PubMed ID: 23036663
[TBL] [Abstract][Full Text] [Related]
8. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
9. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
Słowik-Gabryelska A; Szczepanik A; Kalicka A
Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
[TBL] [Abstract][Full Text] [Related]
10. Health state utility scores in advanced non-small cell lung cancer.
Doyle S; Lloyd A; Walker M
Lung Cancer; 2008 Dec; 62(3):374-80. PubMed ID: 18467000
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
12. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Reck M; Taylor F; Penrod JR; DeRosa M; Morrissey L; Dastani H; Orsini L; Gralla RJ
J Thorac Oncol; 2018 Feb; 13(2):194-204. PubMed ID: 29129758
[TBL] [Abstract][Full Text] [Related]
13. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients.
Lin S; Chen Y; Yang L; Zhou J
J Clin Nurs; 2013 May; 22(9-10):1281-90. PubMed ID: 23574291
[TBL] [Abstract][Full Text] [Related]
14. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients surviving non-small cell lung cancer.
Grutters JP; Joore MA; Wiegman EM; Langendijk JA; de Ruysscher D; Hochstenbag M; Botterweck A; Lambin P; Pijls-Johannesma M
Thorax; 2010 Oct; 65(10):903-7. PubMed ID: 20861294
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of patients with fibromyalgia in France and Germany.
Perrot S; Winkelmann A; Dukes E; Xu X; Schaefer C; Ryan K; Chandran A; Sadosky A; Zlateva G
Int J Clin Pract; 2010 Jul; 64(8):1100-8. PubMed ID: 20497264
[TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study.
Quist M; Rørth M; Langer S; Jones LW; Laursen JH; Pappot H; Christensen KB; Adamsen L
Lung Cancer; 2012 Feb; 75(2):203-8. PubMed ID: 21816503
[TBL] [Abstract][Full Text] [Related]
18. The relationship between cigarette smoking and quality of life after lung cancer diagnosis.
Garces YI; Yang P; Parkinson J; Zhao X; Wampfler JA; Ebbert JO; Sloan JA
Chest; 2004 Dec; 126(6):1733-41. PubMed ID: 15596667
[TBL] [Abstract][Full Text] [Related]
19. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy.
Ozturk A; Sarihan S; Ercan I; Karadag M
Am J Clin Oncol; 2009 Feb; 32(1):65-72. PubMed ID: 19194128
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
